Dinutuximab
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB09077 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 28 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | vertebral anomalies and variable endocrine and T-cell dysfunction | KG + DL |
| 2 | ganglioneuroblastoma (disease) | KG + DL |
| 3 | retroperitoneal neoplasm | KG + DL |
| 4 | chronic myelogenous leukemia, BCR-ABL1 positive | KG + DL |
| 5 | B-cell neoplasm | KG + DL |
| 6 | myeloid leukemia | KG + DL |
| 7 | lymphoma, non-Hodgkin, familial | KG + DL |
| 8 | hereditary breast ovarian cancer syndrome | KG + DL |
| 9 | follicular lymphoma | KG + DL |
| 10 | pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma | KG + DL |
| 11 | chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation | KG + DL |
| 12 | acute lymphoblastic/lymphocytic leukemia | KG + DL |
| 13 | blast phase chronic myelogenous leukemia, BCR-ABL1 positive | KG + DL |
| 14 | acquired secondary polycythemia | KG + DL |
| 15 | mantle cell lymphoma | KG + DL |
| 16 | lymphosarcoma | KG + DL |
| 17 | congenital secondary polycythemia | KG + DL |
| 18 | colon adenocarcinoma | KG + DL |
| 19 | polycythemia (disease) | KG + DL |
| 20 | bladder transitional cell carcinoma | KG + DL |
| 21 | malignant tumor of meninges | KG + DL |
| 22 | familial thrombocytosis | KG + DL |
| 23 | plasmacytoma | KG + DL |
| 24 | spinal cord cancer | KG + DL |
| 25 | lymphoma | KG + DL |
| 26 | cerebral neuroblastoma | KG + DL |
| 27 | cerebral sarcoma | KG + DL |
| 28 | bladder exstrophy (disease) | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.